Foghorn Therapeutics ( NASDAQ: FHTX ) said it has closed its registered direct offering of common stock and of pre-funded warrants, with gross proceeds of the offering totaling ~$110 million. The gross proceeds will strengthen the firm's balance sheet with cash, cash equivalents and short-term investments of $310 million and extend the cash runway into 2027, the company said. More on Foghorn Therapeutics Foghorn prices $110M mixed-shelf registered direct offering Foghorn Therapeutics appoints Kristian Humer as chief financial officer.
